ArticleBMC veterinary research2026
Pharmacokinetic/pharmacodynamic relationships and development of resistance of enrofloxacin and cefquinome in combination therapy against Klebsiella pneumoniae in chicks.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe antibiotic resistance of Klebsiella pneumoniae poses significant challenges in veterinary clinical settings and threatens poultry production. Veterinarians often employ combination therapy to address this issue. However, the resulting effects are complex and not well understood. This study aims to describe the therapeutic effects of different dosing regimens of enrofloxacin (ENR) and cefquinome (CEQ) in a pharmacokinetic/pharmacodynamic (PK/PD) model using chicks.
methodsThis experiment utilized a chick pneumonia model, and the dosing regimen of the combination drug was divided into three single-dose groups and three split-dose groups for three consecutive days; The PK/PD fitting analysis was conducted using the Inhibitory Sigmoid Emax model; The alterations in bacterial load of drug-resistant K. pneumoniae CLS2 (Clinical strain) were assessed through viable bacterial counts and minimum inhibitory concentration (MIC); Additionally, the resistance mutations and efflux pump activity of the resistant strains were evaluated.
resultsThe MICs of ENR and CEQ for CLS2 were 2 µg/mL and 0.125 µg/mL, respectively. The PD results demonstrated that the efficacy of the split-dose group, which received 20 mg/kg of ENR in combination with 20 mg/kg of CEQ (ΔE = 5.66 Log10 CFU/mL), significantly surpassed that of the single-dose group (ΔE = 2.80 Log10 CFU/mL). The combination therapy group, where CEQ was administered at split doses of 4 and 20 mg/kg demonstrated bactericidal activity (ΔE ≥ 3.05 Log10 CFU/mL) and exhibited a substantial clearance effect against K. pneumoniae, respectively. The PK/PD parameters indicated that the parameter value required to achieve a 3 Log10 CFU/mL reduction for %T > MIC(combined) (R2 > 0.900) was calculated at 37.062.
conclusionsENR administered via intramuscular injection at 10 mg/kg and CEQ at 2.6 mg/kg both twice daily for three consecutive days was effective for addressing pulmonary infections in chicks induced by K. pneumoniae and may also help postpone the development of antibiotic resistance. Furthermore, a thoughtfully formulated combination therapy approach could potentially mitigate the rise of resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.